O-GlcNAcylation of enolase 1 serves as a dual regulator of aerobic glycolysis and immune evasion in colorectal cancer
Proceedings of the National Academy of Sciences · 29.10.2024 · 121 (44)
DOI: 10.1073/pnas.2408354121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 24.10.2024. Verfasst von Qiang Zhu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, College of Life Sciences, Zhejiang University, Hangzhou 310058, China. Hauptthemen laut MEDLINE: Phosphopyruvate Hydratase, Glycolysis, Colorectal Neoplasms, Tumor Suppressor Proteins. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
Aerobic glycolysis and immune evasion are two key hallmarks of cancer. However, how these two features are mechanistically linked to promote tumor growth is not well understood. Here, we show that the glycolytic enzyme enolase-1 (ENO1) is dynamically modified with an O -linked β- N -acetylglucosamine (O-GlcNAcylation), and simultaneously regulates aerobic glycolysis and immune evasion via differential glycosylation. Glycosylation of threonine 19 (T19) on ENO1 promotes its glycolytic activity via the formation of active dimers. On the other hand, glycosylation of serine 249 (S249) on ENO1 inhibits its interaction with PD-L1, decreases association of PD-L1 with the E3 ligase STUB1, resulting in stabilization of PD-L1. Consequently, blockade of T19 glycosylation on ENO1 inhibits glycolysis, and decreases cell proliferation and tumor growth. Blockade of S249 glycosylation on ENO1 reduces PD-L1 expression and enhances T cell–mediated immunity against tumor cells. Notably, elimination of glycosylation at both sites synergizes with PD-L1 monoclonal antibody therapy to promote antitumor immune response. Clinically, ENO1 glycosylation levels are up-regulated and show a positive correlation with PD-L1 levels in human colorectal cancers. Thus, our findings provide a mechanistic understanding of how O-GlcNAcylation bridges aerobic glycolysis and immune evasion to promote tumor growth, suggesting effective therapeutic opportunities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, College of Life Sciences, Zhejiang University, Hangzhou 310058, China.
- Department of Biophysics, College of Life Sciences, Zhejiang University, Hangzhou 310058, China.
- State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing 100026, China.
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang Provincial Key Laboratory of Pancreatic Disease, School of Medicine, Zhejiang University, Hangzhou 310002, China.
- Division of Chemistry & Chemical Engineering, California Institute of Technology, Pasadena, CA 91125.
ORCID-Profile: Zhiya Fan, Siyuan Chai, Bingyi Lin, Yong Wang, Linda C Hsieh-Wilson, Wen Yi
Förderung
- NIA NIH HHS
Zitieren
APA
Zhu, Q., Li, J., Sun, H., Fan, Z., Hu, J., Chai, S., Lin, B., Wu, L., Qin, W., Wang, Y., Hsieh-Wilson, L. C., & Yi, W. (2024). O-GlcNAcylation of enolase 1 serves as a dual regulator of aerobic glycolysis and immune evasion in colorectal cancer. Proceedings of the National Academy of Sciences, 121(44). https://doi.org/10.1073/pnas.2408354121
Vancouver
Zhu Q, Li J, Sun H, Fan Z, Hu J, Chai S, et al. O-GlcNAcylation of enolase 1 serves as a dual regulator of aerobic glycolysis and immune evasion in colorectal cancer. Proceedings of the National Academy of Sciences. 2024;121(44). doi:10.1073/pnas.2408354121
BibTeX
@article{Zhu2024,
author = {Zhu, Qiang and Li, Jingchao and Sun, Haofan and Fan, Zhiya and Hu, Jiating and Chai, Siyuan and Lin, Bingyi and Wu, Liming and Qin, Weijie and Wang, Yong and Hsieh-Wilson, Linda C and Yi, Wen},
title = {O-GlcNAcylation of enolase 1 serves as a dual regulator of aerobic glycolysis and immune evasion in colorectal cancer},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
volume = {121},
number = {44},
doi = {10.1073/pnas.2408354121}
}
EUVIMED